However, the analgesic action of RBM-007 in bone cancer pain cannot be explained simply by reduced NGF activity, since RBM-007 is ineffective in a rat model of postoperative pain, in which anti-NGF aptamer is effective to attenuate postoperative pain [16]. This evidence concerns the gene NGF and bone cancer.